DSDaniel Silman

Daniel Silman

*This is an algorithmically generated author record based on publicly available information.

Daniel Silman has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal validation of the Maudsley 3-item visual analogue scale (M3VAS): a new, brief, patient-reported outcome measure of depression

    by Daniel Silman, Maria Elena Middag, Anthony J. Cleare, Allan H. Young, Rebecca Strawbridge

    Background: The Maudsley 3-item visual analogue scale (M3VAS) was developed as a novel and intuitive patient-reported measure for depression, focusing on core symptoms and suicidality. Aims: To evaluate the longitudinal validity of M3VAS for capturing symptom change over time. Method: Both M3VAS and the Patient Health Questionnaire (PHQ-9, as reference standard) were administered in an observational study (RHAPSODY, no. NCT04939818) at weeks 0, 2 and 4 to both depressed patients ( n = 50) and matched controls ( n = 24). We serially tested factor structure, internal consistency and convergence (correlation) over time, assessing responsiveness by both correlation of change in score and effect of time across scales (analysis of variance and effect size). Results: M3VAS exhibited strong factor loadings and high item interrelatedness (Cronbach’s alpha 0.78–0.83) at all time points. Total scores correlated strongly with PHQ-9 at each time point ( r > 0.8, P < 0.001). Correlation of score change over the study period ( r = 0.65, P < 0.001) also confirmed responsiveness. In the depressed group, an effect of time on score was seen for both M3VAS ( F = 4.942, P = 0.010) and PHQ-9 ( F = 12.505, P < 0.001), with standard response mean (Cohen’s d ) of 0.58 and 0.74, respectively. No effect of time was seen in the control group. Conclusions: Following previous cross-sectional validation against the Quick Inventory of Depressive Symptomatology–Self-report, this present study demonstrated appropriate longitudinal measurement properties for M3VAS as a measure of depression, including responsiveness. Evaluating the ability of M3VAS to discern responses with a variety of treatments is a key future goal.

  • Open Access

    Clozapine and Sweet's syndrome: case report

    by Apphia Bunting, Daniel Silman, Minesh Karia, Sophie Johnson

    A patient developed fever, raised inflammatory markers and a maculopapular rash following commencement of clozapine for treatment of his schizoaffective disorder. Skin biopsy confirmed Sweet's syndrome. Identification of the cause was challenging, with a number of possible considerations including infection, malignancy and various potential drug triggers. This case highlights the difficulties in the diagnosis of Sweet's syndrome, as well as in identifying the original trigger, which can have significant consequences for management. Withdrawal of potentially causative drugs must be balanced with their benefits, and decisions must be made in the best interests of the patient. Following two courses of prednisolone and withdrawal of clozapine, the patient's rash and systemic symptoms resolved. This confirmed the diagnosis of drug-induced Sweet's syndrome, with clozapine as the offending agent. His mental state stabilised on an alternative antipsychotic.


  • Open Access

    Ketamine’s pharmacokinetic and pharmacodynamic interactions with anticonvulsants, and their implications for psychiatry: A scoping review protocol

    by Hans-Christian Stein, Rebecca Strawbridge, Daniel Silman, Pietro Carmellini, Allan H. Young, Mario F. Juruena

    Considering the ever-increasing use of ketamine as a rapid-acting and efficacious agent for difficult-to-treat affective disorders, it is paramount that clinicians understand pharmacological interactions between ketamine and other drugs commonly used in unipolar and bipolar depression. Anticonvulsants appear of particular interest in this context, as some (valproate, lamotrigine, carbamazepine, pregabalin, gabapentin) are widely employed as mood-stabilisers and/or anxiolytics, while others are still commonly encountered due to the significant comorbidity between affective disorders and epilepsy. This is the protocol for a scoping review aiming to comprehensively collect evidence regarding pharmacodynamic and pharmacokinetic interactions between ketamine (and its enantiomers) and anticonvulsants. Our review was designed in accordance with the PRISMA Extension for Scoping Reviews (PRISMA-ScR). PubMed, Embase, PsycINFO, ProQuest and ClinicalTrials.gov will be searched for relevant papers. Primary and non-primary research of any design will be included to ensure comprehensiveness. All data will be synthetised and presented in narrative form. We anticipate that our results will provide useful insight for clinicians and highlight gaps in knowledge that may be explored in future research.


  • How effective is augmentation with psychotherapy as a next-step option for treatment-resistant depression?

    by Daniel Silman

    Determining the optimum next-step treatment for the numerous patients with depression who do not adequately respond to an initial trial of medication remains a source of uncertainty in clinical practice. Although a number of psychological treatments are known to be effective for depression, their relative merits in the treatment-resistant group have not been ascertained. The Cochrane Collaboration has recently published a meta-analysis of the evidence available for the use of various psychotherapies as an adjunct to antidepressants compared with antidepressants alone in treatment-resistant depression. This article provides a commentary and appraisal of the clinical utility of these findings.

  • Prime and target immunization protects against liver-stage malaria in mice

    by Anita Gola, Daniel Silman, Adam A. Walters, Saranya Sridhar, Stefan Uderhardt, Ahmed M. Salman, Benedict R. Halbroth, Duncan Bellamy, Georgina Bowyer, Jonathan Powlson, et al.

    Despite recent advances in treatment and vector control, malaria is still a leading cause of death, emphasizing the need for an effective vaccine. The malaria life cycle can be subdivided into three stages: the invasion and growth within liver hepatocytes (pre-erythrocytic stage), the blood stage (erythrocytic stage), and, finally, the sexual stage (occurring within the mosquito vector). Antigen (Ag)-specific CD8+ T cells are effectively induced by heterologous prime-boost viral vector immunization and known to correlate with liver-stage protection. However, liver-stage malaria vaccines have struggled to generate and maintain the high numbers of Plasmodium-specific circulating T cells necessary to confer sterile protection. We describe an alternative “prime and target” vaccination strategy aimed specifically at inducing high numbers of tissue-resident memory T cells present in the liver at the time of hepatic infection. This approach bypasses the need for very high numbers of circulating T cells and markedly increases the efficacy of subunit immunization against liver-stage malaria with clinically relevant Ags and clinically tested viral vectors in murine challenge models. Translation to clinical use has begun, with encouraging results from a pilot safety and feasibility trial of intravenous chimpanzee adenovirus vaccination in humans. This work highlights the value of a prime-target approach for immunization against malaria and suggests that this strategy may represent a more general approach for prophylaxis or immunotherapy of other liver infections and diseases.